ARTICLE | Translation in Brief
NYU cuts to the bone with MRCT
Why NYU thinks MRCT partnership can develop antibodies for osteolysis
May 7, 2015 7:00 AM UTC
New York University School of Medicine expects its recent deal with the not-for-profit MRC Technology will help the university extract more value from its therapeutic targets than if it had partnered them with a biotech or pharma company at the same stage.
On April 23, NYU and MRCT announced a collaboration to develop therapeutic antibodies against targets identified at NYU to treat inflammatory osteolysis, a disease that involves breakdown and resorption of bone by osteoclasts. ...